Aurora Kinase A inhibitor alisertib failed to exert its efficacy on TNBC cells due to consequential enrichment of polyploid giant cancer cells (PGCCs)
{{output}}
Background: Kinases are emerging as promising targetable choices for Triple negative breast cancer (TNBC) patients who suffer from lack of targeted therapy. Aurora kinase A (AURKA) inhibitor alisertib although showed promise but ... ...
